JOP20240250A1 - مركبات واستخداماتها - Google Patents

مركبات واستخداماتها

Info

Publication number
JOP20240250A1
JOP20240250A1 JOJO/P/2024/0250A JOP20240250A JOP20240250A1 JO P20240250 A1 JOP20240250 A1 JO P20240250A1 JO P20240250 A JOP20240250 A JO P20240250A JO P20240250 A1 JOP20240250 A1 JO P20240250A1
Authority
JO
Jordan
Prior art keywords
vehicles
cancer
formula
present disclosure
pharmaceutically acceptable
Prior art date
Application number
JOJO/P/2024/0250A
Other languages
Arabic (ar)
English (en)
Inventor
Melek Nihan Ucisik
Shawn E R Schiller
Richard Caldwell
Solymar Negretti
David S Huang
Kevin J Wilson
Original Assignee
Foghorn Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foghorn Therapeutics Inc filed Critical Foghorn Therapeutics Inc
Publication of JOP20240250A1 publication Critical patent/JOP20240250A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JOJO/P/2024/0250A 2022-05-11 2024-11-07 مركبات واستخداماتها JOP20240250A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263340927P 2022-05-11 2022-05-11
PCT/US2023/021793 WO2023220219A1 (en) 2022-05-11 2023-05-11 Compounds and uses thereof

Publications (1)

Publication Number Publication Date
JOP20240250A1 true JOP20240250A1 (ar) 2024-11-07

Family

ID=86732694

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2024/0250A JOP20240250A1 (ar) 2022-05-11 2024-11-07 مركبات واستخداماتها

Country Status (17)

Country Link
US (2) US12139487B2 (cg-RX-API-DMAC7.html)
EP (1) EP4522280A1 (cg-RX-API-DMAC7.html)
JP (2) JP7531656B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250024923A (cg-RX-API-DMAC7.html)
CN (1) CN119677738A (cg-RX-API-DMAC7.html)
AR (1) AR129299A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023270055A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252955A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003450A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024015229A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000231A (cg-RX-API-DMAC7.html)
IL (1) IL316531A (cg-RX-API-DMAC7.html)
JO (1) JOP20240250A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013838A (cg-RX-API-DMAC7.html)
PE (1) PE20250261A1 (cg-RX-API-DMAC7.html)
TW (2) TW202506693A (cg-RX-API-DMAC7.html)
WO (1) WO2023220219A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3198317A1 (en) * 2020-11-10 2022-05-19 Kevin J. Wilson Compounds and uses thereof
WO2025008060A1 (en) * 2023-07-05 2025-01-09 Janssen Pharmaceutica Nv 1,6-naphthridine compounds as smarca2 inhibitors useful for the treatment of smarca4 deficient cancers
WO2025099307A1 (en) * 2023-11-10 2025-05-15 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of diseases
US20250304542A1 (en) * 2024-03-11 2025-10-02 Enanta Pharmaceuticals, Inc. Fused Heterobicyclic Antiviral Agents
WO2025209520A1 (zh) * 2024-04-03 2025-10-09 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其用途
WO2025237242A1 (zh) * 2024-05-14 2025-11-20 上海和誉生物医药科技有限公司 一种smarca2抑制剂及其应用
CN118930537B (zh) * 2024-07-23 2025-05-13 上海信诺维生物医药有限公司 一种抑制brm的化合物
CN118930561B (zh) * 2024-07-23 2025-04-08 上海信诺维生物医药有限公司 一种稠环化合物
CN118908980B (zh) * 2024-07-23 2025-04-08 上海信诺维生物医药有限公司 一种多环化合物
WO2026046365A1 (zh) * 2024-08-30 2026-03-05 上海齐鲁制药研究中心有限公司 Smarca2抑制剂及其制备方法和用途
WO2026057002A1 (zh) * 2024-09-12 2026-03-19 江苏恒瑞医药股份有限公司 一种烯炔类化合物及其应用
WO2026061424A1 (zh) * 2024-09-18 2026-03-26 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其用途
WO2026131996A1 (en) * 2024-12-17 2026-06-25 Onco3R Therapeutics Bv Fused azines for the treatment of cancer
WO2026158636A1 (zh) * 2025-01-26 2026-07-30 江苏恒瑞医药股份有限公司 一种三环骨架芳酰胺类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007243466B2 (en) 2006-04-26 2012-01-19 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
SG10201900631TA (en) 2014-08-01 2019-02-27 Nuevolution As Compounds active towards bromodomains
BR112022015110A2 (pt) 2020-01-29 2022-11-08 Foghorn Therapeutics Inc Compostos e usos dos mesmos
BR112022015109A2 (pt) * 2020-01-29 2022-11-08 Foghorn Therapeutics Inc Compostos e usos dos mesmos
WO2021155264A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155262A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
CA3198317A1 (en) 2020-11-10 2022-05-19 Kevin J. Wilson Compounds and uses thereof

Also Published As

Publication number Publication date
TW202411228A (zh) 2024-03-16
AR129299A1 (es) 2024-08-07
JP7531656B2 (ja) 2024-08-09
AU2023270055A1 (en) 2024-11-28
MX2024013838A (es) 2025-03-07
KR20250024923A (ko) 2025-02-20
CO2024015229A2 (es) 2025-03-06
TWI864749B (zh) 2024-12-01
CA3252955A1 (en) 2023-11-16
DOP2024000231A (es) 2024-12-15
PE20250261A1 (es) 2025-01-29
EP4522280A1 (en) 2025-03-19
JP2023168298A (ja) 2023-11-24
TW202506693A (zh) 2025-02-16
US20230365560A1 (en) 2023-11-16
IL316531A (en) 2024-12-01
CN119677738A (zh) 2025-03-21
US12139487B2 (en) 2024-11-12
WO2023220219A1 (en) 2023-11-16
US20250066354A1 (en) 2025-02-27
JP2024156779A (ja) 2024-11-06
CL2024003450A1 (es) 2025-03-14

Similar Documents

Publication Publication Date Title
MX2024013838A (es) Compuestos y usos de estos
ZA202403923B (en) Heterocyclic compounds as immunomodulators
JOP20230318A1 (ar) مشتقات تترا هيدرو – إيميدازوبيريدين كمعدِّلات مناعية pd-l1
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
JOP20200315A1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
MY209609A (en) Immunomodulators, compositions and methods thereof
CR20230566A (es) Derivados de triazina y su uso en el tratamiento del cáncer
JOP20230277A1 (ar) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز (pi3k) لعلاج الأمراض
WO2019139899A8 (en) Benzamide compounds
MX2022009043A (es) Compuestos de sulfonimidamida como moduladores de nlrp3.
EA200801041A1 (ru) Ингибиторы мек и способы их применения
AU2020231934A8 (en) Compounds useful in HIV therapy
MX2024013842A (es) Benzoyparazina pirazinas y sus usos
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
EP4316504A3 (en) Compounds
ZA202006071B (en) Antiproliferation compounds and uses thereof
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
MX2025001062A (es) Derivados de heteroaril sulfonamida biciclicos sustituidos para el tratamiento del cancer
JOP20190179A1 (ar) نوكليوتيدات ثنائية حلقية كناهضات لـ sting
JOP20230275A1 (ar) معدلات trex1
JOP20240130A1 (ar) مثبطات تفاعل منين-mll
MX2024013840A (es) Derivados de pirazina y usos de los mismos